Top Markets
Coin of the day
Onward Medical N.V. Onward Medical N.V.

Onward Medical N.V.

ONWD
Rank in Stocks #20475
Onward Medical N.V. is a medical technology company dedicated to developing... Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.
Share Price
$2.75
Market Cap
$128.44M
Change (1 day)
-2.11%
Change (1 year)
-53.60%
Country
NL
Trade Onward Medical N.V. (ONWD)

Category

Revenue for Onward Medical N.V. (ONWD)
Revenue in Aug 2026 TTM: 0
According to Onward Medical N.V. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Onward Medical N.V. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH